Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Bioinicia is a Spanish nanotechnology and pharmaceutical manufacturing company focused on electrospinning and electrospraying for drug delivery, medical, and related healthcare applications. Founded as a CSIC spin-off, it operates GMP- and ISO 13485-certified facilities and provides contract development and manufacturing services for electrospun fibers, particles, patches, films, and other advanced dosage forms. The company also sells specialized equipment under the Fluidnatek and Spinbox brands for research, pilot, and industrial production. In pharmaceuticals, Bioinicia emphasizes platform technologies such as mucoadhesive and sublingual patches, transdermal systems, oral dissolving films, enteric encapsulation, and Nano-in-Micro particle formulations. Its best-publicized development example is the Rivelin mucosal drug delivery patch for oral lichen planus, described on its website as being in Phase 2b clinical testing.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Bioinicia.